Stability To Scalability: The Future Of Viral Vector Therapies

Several advances have already contributed to improvements in viral vector yields. Yet, the CGT sector is still in need of innovations in all aspects of the process to impact product quality. During this Cell & Gene Live webinar, Chief Editor, Erin Harris welcomed Dave Maheu, Vice President, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO for a discussion on accelerating scale for viral vector production. Available on-demand thanks to the support of Thermo Fisher Scientific.